Log in

NASDAQ:TECHBIO-TECHNE Stock Price, Forecast & News

$272.40
-4.97 (-1.79 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$271.54
Now: $272.40
$278.53
50-Day Range
$242.03
MA: $259.45
$274.01
52-Week Range
$155.17
Now: $272.40
$282.52
Volume135,900 shs
Average Volume189,576 shs
Market Capitalization$10.41 billion
P/E Ratio57.59
Dividend Yield0.47%
Beta1.14
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, such as cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment offers Biologics tools for researchers to interrogate protein purity and identify contaminants during the development and production of biologics; Western blot, an assay for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment provides blood chemistry and gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market. Bio-Techne Corporation has a strategic cooperation agreement with Micropoint Bioscience. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. It has strategic partnership with NanoString Technologies. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Read More
BIO-TECHNE logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.3Dividend Strength: 1.7Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.70 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:TECH
CUSIP87837710
Phone612-379-8854

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$714.01 million
Cash Flow$5.97 per share
Book Value$30.78 per share

Profitability

Net Income$96.07 million

Miscellaneous

Employees2,250
Market Cap$10.41 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive TECH News and Ratings via Email

Sign-up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter.

BIO-TECHNE (NASDAQ:TECH) Frequently Asked Questions

How has BIO-TECHNE's stock been impacted by COVID-19 (Coronavirus)?

BIO-TECHNE's stock was trading at $180.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TECH stock has increased by 50.8% and is now trading at $272.40. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of BIO-TECHNE?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BIO-TECHNE.

When is BIO-TECHNE's next earnings date?

BIO-TECHNE is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for BIO-TECHNE.

How were BIO-TECHNE's earnings last quarter?

BIO-TECHNE Corp (NASDAQ:TECH) issued its quarterly earnings results on Thursday, April, 30th. The biotechnology company reported $1.39 earnings per share for the quarter, beating analysts' consensus estimates of $1.15 by $0.24. The biotechnology company earned $194.70 million during the quarter, compared to analysts' expectations of $182.32 million. BIO-TECHNE had a net margin of 24.77% and a return on equity of 13.04%. The business's revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.21 earnings per share. View BIO-TECHNE's earnings history.

How often does BIO-TECHNE pay dividends? What is the dividend yield for BIO-TECHNE?

BIO-TECHNE declared a quarterly dividend on Tuesday, February 4th. Shareholders of record on Friday, February 14th will be paid a dividend of $0.32 per share on Friday, February 28th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.47%. The ex-dividend date is Thursday, February 13th. View BIO-TECHNE's dividend history.

What price target have analysts set for TECH?

9 equities research analysts have issued 12-month target prices for BIO-TECHNE's shares. Their forecasts range from $211.00 to $290.00. On average, they anticipate BIO-TECHNE's stock price to reach $245.50 in the next year. This suggests that the stock has a possible downside of 9.9%. View analysts' price targets for BIO-TECHNE.

Has BIO-TECHNE been receiving favorable news coverage?

Media coverage about TECH stock has trended neutral on Sunday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. BIO-TECHNE earned a coverage optimism score of 0.5 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about BIO-TECHNE.

Are investors shorting BIO-TECHNE?

BIO-TECHNE saw a decrease in short interest during the month of June. As of June 15th, there was short interest totaling 552,900 shares, a decrease of 10.8% from the May 31st total of 619,700 shares. Based on an average daily trading volume, of 299,400 shares, the days-to-cover ratio is currently 1.8 days. Currently, 1.5% of the company's stock are sold short. View BIO-TECHNE's Current Options Chain.

Who are some of BIO-TECHNE's key competitors?

What other stocks do shareholders of BIO-TECHNE own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BIO-TECHNE investors own include AbbVie (ABBV), NVIDIA (NVDA), Paychex (PAYX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Netflix (NFLX), Pfizer (PFE), Thermo Fisher Scientific (TMO), Advanced Micro Devices (AMD) and Amgen (AMGN).

Who are BIO-TECHNE's key executives?

BIO-TECHNE's management team includes the following people:
  • Mr. Charles R. Kummeth, CEO, Pres & Director (Age 59)
  • Mr. James T. Hippel, Sr. VP of Fin. & CFO (Age 48)
  • Ms. Brenda S. Furlow, Gen. Counsel, Sec. & Chief Compliance Officer (Age 61)
  • Mr. N. David Eansor, Pres of Protein Sciences Segment (Age 58)
  • Mr. Gerry Andros, VP of Sales and Marketing

What is BIO-TECHNE's stock symbol?

BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."

Who are BIO-TECHNE's major shareholders?

BIO-TECHNE's stock is owned by a variety of institutional and retail investors. Top institutional investors include Riverbridge Partners LLC (1.01%), Envestnet Asset Management Inc. (0.08%), State of Alaska Department of Revenue (0.04%), Diversified Trust Co (0.01%), IBM Retirement Fund (0.00%) and Contravisory Investment Management Inc. (0.00%). Company insiders that own BIO-TECHNE stock include Brenda S Furlow, Charles A Dinarello, Charles R Kummeth, Harold J Wiens, James Hippel, John L Higgins, Norman David Eansor, Robert V Baumgartner and Roeland Nusse. View institutional ownership trends for BIO-TECHNE.

Which major investors are buying BIO-TECHNE stock?

TECH stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Riverbridge Partners LLC, Envestnet Asset Management Inc., IBM Retirement Fund, Modus Advisors LLC, Diversified Trust Co, Carroll Financial Associates Inc., and Contravisory Investment Management Inc.. Company insiders that have bought BIO-TECHNE stock in the last two years include Charles R Kummeth, and Robert V Baumgartner. View insider buying and selling activity for BIO-TECHNE.

How do I buy shares of BIO-TECHNE?

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BIO-TECHNE's stock price today?

One share of TECH stock can currently be purchased for approximately $272.40.

How big of a company is BIO-TECHNE?

BIO-TECHNE has a market capitalization of $10.41 billion and generates $714.01 million in revenue each year. The biotechnology company earns $96.07 million in net income (profit) each year or $3.80 on an earnings per share basis. BIO-TECHNE employs 2,250 workers across the globe.

What is BIO-TECHNE's official website?

The official website for BIO-TECHNE is www.techne-corp.com.

How can I contact BIO-TECHNE?

BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]

This page was last updated on 7/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.